Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

News Briefs: Approvals For Abbott’s MitraClip, Allergan’s Juvéderm; Diagnostics News

This article was originally published in The Gray Sheet

Executive Summary

FDA approved Abbott’s MitraClip to treat mitral regurgitation and Allergan’s Juvéderm Voluma XC facial filler to temporary correct volume-loss. Hepatitis C testing will be mandatory in New York. More news.

You may also be interested in...



US Heart Valve Treatments Market Fueled By New Transcatheter Valves

The US heart valve treatments market will reach $1.7 billion by 2019, driven by advances in percutaneous heart valve repair and replacement products and a growing number of competitors entering this space. With US sales of transcatheter aortic valve replacement systems set to almost triple in the next several years, the combined US market for products to treat heart valve disorders is expected to grow at a CAGR of 7.7%.

Medicare Will Cover Hepatitis C Screening For Baby Boomers, High Risk Populations

CMS finalized a decision to cover screening for the Hepatitis C virus under Medicare for all adults born between 1945 and 1965, and all “high risk” adults.

Trans-Mitral Valve Repair Gains Medicare Coverage-With-Evidence Proposal

A new draft national Medicare coverage policy offers to pay for transcatheter mitral valve repair procedures with devices like Abbott’s MitraClip only if they are conducted by a qualified heart team and are part of a national registry.

Related Content

Topics

Related Companies

Related Deals

Latest News
See All
UsernamePublicRestriction

Register

MT032538

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel